Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
The Clinical and Laboratory Standards Institute has published “M54-APrinciples and Procedures for Detection of Fungi in Clinical Specimens-Direct Examination and Culture; Approved Guideline.” The document addresses the protocols for detecting fungi in clinical specimens and highlights direct microscopic examinations and fungal culturing methods.
Qiagen has submitted to the FDA its Therascreen EGFR RGQ PCR kit as a proposed companion diagnostic test to guide treatment with afatinib, an investigational oncology compound developed by Boehringer Ingelheim. The FDA has accepted afatinib for filing and granted it priority review as a proposed treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation detected by an FDA-approved test.
Smart Imaging Technologies’ Simagis Live Web Pathology Platform version 4.0, launched last month, makes the transition to digital pathology simple and affordable. With Simagis cloud software, pathologists can connect scanners to a private cloud server and start collaborating.
Insight Genetics has received from the National Cancer Institute two small business innovation research contracts to continue its work developing diagnostic tests that identify and characterize specific genetic mutations in lung cancer patients.
Computype, in partnership with Nautilus Systems, launched the Flexible Tube and Vial Feeder (Flex TVF), a system for automatic downstream tube and vial feeding that increases efficiency.
Chembio Diagnostics has received FDA approval to market its point-of-care Dual Path Platform (DPP) HIV 1/2 assay for the rapid detection of HIV-1/2 antibodies in oral fluid or blood samples.
Akonni Biosystems recently announced results from three preclinical studies verifying the efficacy of its TruDiagnosis molecular diagnostic platform. Akonni TruArray tests are for mid-multiplex molecular diagnostics deployed in near point-of-care settings.
Cellular Engineering Technologies and the nonprofit John Paul II Medical Research Institute (JP2MRI) are partnering to develop a private stem cell biobank. The collaboration will create more than 5,000 patient- and disease-specific stem cell lines and other human cell lines to advance drug discovery and offer personalized medicine. These cell lines are derived from adult sources and do not include embryonic stem cells.
Luminex has received FDA clearance for its xTAG gastrointestinal pathogen panel (GPP), which is a comprehensive molecular diagnostic assay that tests for greater than 90 percent of bacterial, viral, and parasitic causes of infectious gastroenteritis.
DiaSorin has received FDA clearance for its Liaison direct renin immunoassay to aid in the diagnosis and treatment of certain types of hypertension.
